LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its first-quarter 2026 Form 10-Q, highlighting continued advancement of its lead oncology candidate, LB-100, including expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. The company also reported continued growth at its recently acquired Liora Technologies Europe subsidiary as it pursues broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
LB-100 is a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
The expansion of the ovarian cancer trial signals progress in a critical area of unmet medical need. Ovarian clear cell carcinoma is a rare but aggressive subtype that often responds poorly to standard treatments. The favorable safety findings with LB-100 in combination with immunotherapy could pave the way for new combination regimens that improve patient outcomes. For leaders in the biotech and pharmaceutical industries, this development underscores the growing promise of PP2A inhibition as a therapeutic strategy.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. The continued growth at Liora Technologies adds a med-tech dimension to LIXTE’s oncology portfolio, potentially offering synergistic opportunities in cancer treatment.
For investors and industry observers, LIXTE’s dual focus on a novel small molecule and advanced radiation therapy highlights a strategic approach to addressing cancer from multiple angles. The company’s progress in both areas could influence the competitive landscape in oncology, particularly if LB-100 succeeds in clinical trials and the LiGHT System gains regulatory traction. More information on the first-quarter progress is available in the full press release at https://ibn.fm/oHzhK.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Additional information can be found at www.lixte.com and for Liora Technologies at www.lioratechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT.
